PE20161374A1 - Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina - Google Patents

Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina

Info

Publication number
PE20161374A1
PE20161374A1 PE2016001444A PE2016001444A PE20161374A1 PE 20161374 A1 PE20161374 A1 PE 20161374A1 PE 2016001444 A PE2016001444 A PE 2016001444A PE 2016001444 A PE2016001444 A PE 2016001444A PE 20161374 A1 PE20161374 A1 PE 20161374A1
Authority
PE
Peru
Prior art keywords
cyclopentanes
tetrahydrofurans
compounds
receptor antagonists
orexin receptor
Prior art date
Application number
PE2016001444A
Other languages
English (en)
Inventor
Charlotte Fieldhouse
John Stephen Robinson
Angela Glen
Tatsuhiko Fujimoto
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20161374A1 publication Critical patent/PE20161374A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a compuestos de formula I o sales farmaceuticamente aceptables de los mismos, donde: R1 es un grupo heteroaromatico biciclico fusionado de 8 a 10 miembros opcionalmente sustituidos; L es un enlace, CH2, O, NH o N(CH3); Ra y Rb es hidrogeno, alquilo C1-C3 o haloalquilo C1-C3; X es CF2, O, entre otros; R2 es hidrogeno, alquilo C1-C6 o cicloalquilo C3-C6; R3 es un grupo heteroaromatico monociclico de 5 a 6 miembros opcionalmente sustituidos. Son compuestos preferidos: 3-bromo-N-[(1S,2S)-2-[(6-fluoro-1,3-benzotiazol-2-il)amino]ciclopentil]-piridina-2-carboxamida, 6-bromo-N-[(1S,2S)-2-[(6-fluoro-1,3-benzotiazol-2-il)amino]ciclopentil]-3-metoxipiridina-2-carboxamida, entre otros. Tambien se refiere a un proceso de preparacion y a una composicion farmaceutica. Dichos compuestos son antagonistas del receptor sub-tipo 1 de orexina, siendo utiles en el tratamiento de esquizofrenia, demencia, adiccion, entre otros
PE2016001444A 2014-02-20 2015-02-19 Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina PE20161374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14156010 2014-02-20

Publications (1)

Publication Number Publication Date
PE20161374A1 true PE20161374A1 (es) 2016-12-17

Family

ID=50115775

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001444A PE20161374A1 (es) 2014-02-20 2015-02-19 Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina

Country Status (20)

Country Link
US (1) US9790220B2 (es)
EP (1) EP3107907A1 (es)
JP (1) JP6466465B2 (es)
KR (1) KR20160124188A (es)
CN (1) CN106164064B (es)
AU (1) AU2015220553B2 (es)
CA (1) CA2940047A1 (es)
CL (1) CL2016002085A1 (es)
CR (1) CR20160373A (es)
EA (1) EA031982B1 (es)
EC (1) ECSP16074482A (es)
GE (1) GEP20186909B (es)
IL (1) IL247195A0 (es)
MA (1) MA39229A1 (es)
MX (1) MX2016010745A (es)
PE (1) PE20161374A1 (es)
PH (1) PH12016501625A1 (es)
SG (1) SG11201606839SA (es)
WO (1) WO2015124934A1 (es)
ZA (1) ZA201604924B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
WO2015160219A1 (ko) 2014-04-17 2015-10-22 한국생명공학연구원 피스타시아 웨인마니폴리아 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 만성폐쇄성 폐질환(copd) 예방 또는 치료용 약학적 조성물
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
KR102298546B1 (ko) * 2018-10-18 2021-09-08 에이치케이이노엔 주식회사 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399441B1 (en) * 2001-06-28 2006-07-05 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2008038841A1 (fr) * 2006-09-30 2008-04-03 Japan Tobacco Inc. Dérivé de thiadiazolone et utilisation de celui-ci
JP5847087B2 (ja) * 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
NZ703448A (en) * 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives

Also Published As

Publication number Publication date
PH12016501625A1 (en) 2016-11-07
EP3107907A1 (en) 2016-12-28
CN106164064A (zh) 2016-11-23
EA201691673A1 (ru) 2017-01-30
SG11201606839SA (en) 2016-09-29
US9790220B2 (en) 2017-10-17
EA031982B1 (ru) 2019-03-29
MX2016010745A (es) 2017-02-02
CA2940047A1 (en) 2015-08-27
IL247195A0 (en) 2016-09-29
JP6466465B2 (ja) 2019-02-06
WO2015124934A1 (en) 2015-08-27
CR20160373A (es) 2016-12-02
MA39229A1 (fr) 2018-01-31
WO2015124934A8 (en) 2016-07-21
ZA201604924B (en) 2019-04-24
US20170073340A1 (en) 2017-03-16
AU2015220553A1 (en) 2016-07-21
CL2016002085A1 (es) 2017-06-09
ECSP16074482A (es) 2018-05-31
AU2015220553B2 (en) 2019-06-27
GEP20186909B (en) 2018-10-25
JP2017506239A (ja) 2017-03-02
CN106164064B (zh) 2019-03-22
KR20160124188A (ko) 2016-10-26

Similar Documents

Publication Publication Date Title
CO2017000438A2 (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20161443A1 (es) Compuestos
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20161476A1 (es) Derivados de indolin-2-ona o pirrolo-piridin-2-ona
PE20170323A1 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
PE20161407A1 (es) Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
PE20160839A1 (es) Derivados de 4-azaindol
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
PE20161366A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo
PE20161374A1 (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20161315A1 (es) Compuestos de pirazolona y usos de los mismos
PE20161370A1 (es) Nuevos derivados de piridina utiles como antagonistas de cb2
PE20171100A1 (es) Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3